Syntrix research and development program toward developing a spatiotemporal gene control technology was featured in a Microsoft Case Study. Read the article.
Syntrix Reports the Cellular Mechanism of Compounds It Discovered to Treat COPD and Lung Disease in Neonates
Congratulations to Syntrix scientists and their collaborators at Montana State University on their latest publication in The Journal of Pharmacology and Experimental Therapeutics. Signficance: These studies demonstrate that compounds discovered by Syntrix to treat COPD and lung disease in neonates work by inhibiting CXCR1/2, G-protein coupled receptors, via a novel intracellular mechanism. Abstract: The chemokine receptors CXCR1/2 are […]
Congratulations to Syntrix scientists on their new grant for $590K from the National Institute for Arthritis Musculoskeletal and Skin Diseases (NIAMS) of the National Institutes of Health (NIH). The project will be carried out in collaboration with Dr. Larry Matherly’s group at Wayne State University School of Medicine. The project title is “99mTc-DTB-Antifol-Pteroyls (RadioDAPs): Theranostics for Rheumatoid Arthritis.” Here […]
Syntrix was one of 14 breakthrough technology companies invited to present at the 2009 SBIR Investor Forum sponsored by the National Cancer Institute (NCI). The chosen companies were selected from a highly competitive field of applicants by an independent panel of experts from venture capital firms, bio-pharmaceutical and medical device companies, based on their strength of research, impact on […]
Syntrix Reports Discovery of PhotoMorphs: A Novel Light-Activated Reagent for Controlling Gene Expression in Zebrafish
Congratulations to Syntrix scientists and their collaborators at the Medical College of Wisconsin on their latest publication, which appeared in the journal Genesis. The publication describes a novel method for controlling gene expression in living animals using targeted light irradiation. Link to paper.